enhancing cooperative activities between Federal and private sector research organizations. In addition, the National Parks Omnibus Management Act of 1998 (Pub. L. 105–391) specifically authorizes the negotiation of "equitable, efficient benefits-sharing arrangements" between units of the National Park System and the research community.

NPS regulations provide that a park superintendent may issue a permit to a qualifying researcher when it determined that "public health and safety, environmental or scenic values, natural or cultural resources, scientific research, implementation of management responsibilities, proper allocation and use of facilities, or the avoidance of conflict among visitor use activities will be adversely impacted" (36 CFR 1.6(a)). Through a public process, this environmental assessment will examine potential environmental impacts of various methods of implementing the provisions of law that authorizes benefits-sharing agreements while ensuring the integrity of resources.

A newsletter and web site have been prepared with additional information concerning this assessment. Copies of that information may be obtained online at www.nature.nps.gov/benefitsharing or by contacting: NPS Benefits Sharing Team, P.O. Box 168, Yellowstone National Park, WY, 82190; telephone 307-344-2203. Comments may be submitted by any one of several methods. You may mail comments to: National Park Service. Benefit-Sharing Environmental Assessment, P.O. Box 168, Yellowstone National Park, WY 82190. You may also email comments to Benefits EA@nps.gov, or submit them online at www.nature.nps.gov/ benefitssharing. NPS practice is to make comments, including the names and address of respondents, available for public review during regular business hours. Individual respondents may request that NPS withhold their address from the record, which will be honored to the extent allowable by law. There also may be circumstances in which NPS would withhold from the record a respondent's identity, to the extent allowable by law. If you wish the NPS to withhold your name and/or address, you must state this prominently at the beginning of your comments. NPS will make all submissions from organizations and businesses, and from individuals identifying themselves as representatives or officials or organizations or businesses, available for public inspection in their entirety.

DATES: Comments on the potential scope of the assessment, alternatives to be considered, impacts to be addressed, and any other relevant related issues should be submitted on or before August 9, 2001.

FOR FURTHER INFORMATION CONTACT: Sue Mills, National Park Service Benefits Sharing Team, P.O. Box 168, Yellowstone National Park, WY 82190; telephone 307–344–2203.

Dated: June 1, 2001.

Abigail Miller,

Acting Associate Director, Natural Resources Stewardship and Science.

[FR Doc. 01–15559 Filed 6–22–01; 8:45 am] BILLING CODE 4310–70–M

DEPARTMENT OF THE INTERIOR

Office of Surface Mining Reclamation and Enforcement

Notice of Proposed Information Collection

AGENCY: Office of Surface Mining Reclamation and Enforcement. **ACTION:** Notice and request for comments.

SUMMARY: In compliance with the Paperwork Reduction Act of 1995, the Office of Surface Mining Reclamation and Enforcement (OSM) is announcing its intention to renew authority to collect information for a series of customer surveys to evaluate OSM's performance in meeting the performance goals outlined in its annual plans developed pursuant to the Government Performance and Results Act (GPRA). The Office of Management and Budget (OMB) previously approved the collection and assigned it clearance number 1029–0114.

DATES: Comments on the proposed information collection must be received by August 24, 2001, to be assured of consideration.

ADDRESSES: Comments may be mailed to John A. Trelease, Office of Surface Mining Reclamation and Enforcement, 1951 Constitution Ave., NW., Room 210–SIB, Washington, DC 20240. Comments may also be submitted electronically to jtrerleas@osmre.gov.

FOR FURTHER INFORMATION CONTACT: To request a copy of the information collection request, explanatory information and related form, contact John A. Trelease, at (202) 208–2783.

SUPPLEMENTARY INFORMATION: OMB regulations at 5 CFR 1320, which implementing provisions of the Paperwork Reduction Act of 1995 (Pub. L. 104–13), require that interested

members of the public and affected agencies have an opportunity to comment on information collection and recordkeeping activities (see 5 CFR 1320.8 (d)). This notice identifies information collections that OSM will be submitting to OMB for approval. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this collection of information is 1029-0114 and is on the forms along with the expiration date. OSM will request a 3year term of approval for this information collection activity.

Comments are invited on: (1) The need for the collection of information for the performance of the functions of the agency; (2) the accuracy of the agency's burden estimates; (3) ways to enhance the quality, utility and clarity of the information collection; and (4) ways to minimize the information collection burden on respondents, such as use of automated means of collection of the information. A summary of the public comments will accompany OSM's submission of the information collection request to OMB.

This notice provides the public with 60 days in which to comment on the following information collection activity:

Title: Technical Evaluations Series. *OMB Control Number:* 1029–0114.

Summary: The series of surveys are needed to ensure that technical assistance activities, technology transfer activities and technical forums are useful for those who participate or receive the assistance. Specifically, representatives from State and Tribal regulatory and reclamation authorities, representatives of industry, environmental or citizen groups, or the public, are the recipients of the assistance or participants in these forums. These surveys will be the primary means through which OSM evaluates its performance in meeting the performance goals outlines in its annual plans developed pursuant to the Government Performance and Results Act.

Bureau Form Number: None. Frequency of Collection: Once.

Description of Respondents: 26 State and Tribal governments, industry organizations and individuals who request information or assistance.

Total Annual Responses: 750. Total Annual Burden Hours: 125. Drug

Schedule

Dated: June 13, 2001.

Richard G. Bryson,

Chief, Division of Regulatory Support.
[FR Doc. 01–15894 Filed 6–22–01; 8:45 am]
BILLING CODE 4310–05–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated January 25, 2001, and published in the **Federal Register** on February 14, 2001, (66 FR 10320), Cerilliant Corporation, 14050 Summit Drive #121, P.O. Box 201088, Austin, Texas 78708–0189, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule	
Cathinone (1235)	I	
Methcathinone (1237)	1	
N-Ethylamphetamine (1475)	1	
N, N-Dimethylamphetamine	l i	
(1480).		
Aminorex (1585)	l i	
4-Methylaminorex (cis isomer)	li	
(1590).	'	
Gamma hydroxybutyric acid	1	
	'	
(2010). Methaqualone (2565)	1	
	i	
Alpha-Ethyltryptamine (7249)		
Lysergic acid diethylamide (7315)	1 :	
Tetrahydrocannabinols (7370)		
Mescaline (7381)	1	
3,4,5-Trimethoxyamphetamine		
4-Bromo-2, 5-	1	
dimethoxyamphetamine (7390).	ı	
4-Bromo-2, 5-	1	
dimethoxyphenethylamine		
(7392).		
4-Methyl-2, 5-	I	
dimethoxyamphetamine (7395).		
2, 5-Dimethoxyamphetamine	I	
(7396).	1	
2, 5-Dimethoxy-4-	1	
ethylamphetamine (7399).		
3, 4-Methylenedioxyamphetamine	I	
(7400). 5-Methoxy-3. 4-	ı	
·	1	
methylenedioxyamphetamine		
(7401). N-Hvdroxv-3. 4-	ı	
	'	
methylenedioxyamphetamine		
(7402).		
3, 4-Methylenedioxy-N-	I	
ethylamphetamine (7404).	ı	
0,	1	
Methylenedioxymethamphetam-		
ine (7405).		
4-Methoxyamphetamine (7411)		
Bufotenine (7433)		
Diethyltryptamine (7434)		
Dimethyltryptamine (7435)		
Psilocybin (7437)		
Psilocyn (7438)	ļ	

Acetyldihydrocodeine (9051) I

Ronzylmorphino (0052)	1
Benzylmorphine (9052) Codeine-N-oxide (9053)	
Dibudramarshina (0145)	!
Dihydromorphine (9145)	!
Heroin (9200) Morphine-N-oxide (9307)	!
Morphine-N-oxide (9307)	I
Normorphine (9313)	I
Pholcodine (9314)	I
Acetylmethadol (9601)	1
Allyprodine (9602)	i
Alphacetylmethadol except Levo-	i
Alphacetylmethadol (9603).	•
Alphacetylinethadol (9003).	
Alphameprodine (9604)	!
Alphamethadol (9605)	I
Betacetylmethadol (9607)	I
Betameprodine (9608)	1
Betamethadol (9609)	1
Betaprodine (9611)	i
Hydromorphinol (9627)	i
Noracymethadol (9633)	i
	-
Norlevorphanol (9634)	1
Normethadone (9635)	I
rimeperidine (9646)	I
Para-Fluorofentanyl (9812)	1
3-Methylfentanyl (9813)	i
Alpha-methylfentanyl (9814)	i
	-
Acetyl-alpha-methylfentanyl	I
(9815).	
Beta-hydroxyfentanyl (9830)	1
Beta-hydroxy-3-methylfentanyl	1
(9831).	
Alpha-Methylthiofentanyl (9832)	1
	i
3-Methylthiofentanyl (9833)	-
Thiofentanyl (9835)	1
Amphetamine (1100)	II
Methamphetamine (1105)	II
Phenmetrazine (1631)	II
Methylphenidate (1724)	II
Amobarbital (2125)	II
Pentobarbital (2270)	ii
Secobarbital (2315)	ii
201. to the incide (25.10)	
Glutethimide (2550)	II
Nabilone (7379)	II
I-Phenylcyclohexylamine (7460)	II
Phencyclidine (7471)	II
l-	II
Piperidinocyclohexanecarbonitr-	
ile (8603).	
Alphanrodine (0010)	п
Alphaprodine (9010)	II
Cocaine (9041)	II.
Codeine (9050)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	ii
Diphenoxylate (9170)	ii
Depresional (9170)	
Benzoylecgonine (9180)	II.
Ethylmorphine (9190)	Ш
Hydrocodone (9193)	II
Levomethorphan (9210)	II
Levorphanol (9220)	II
Isomethadone (9226)	ii
	ii
Meperidine (9230)	
	II.
Methadone-intermediate (9254)	Ш
Methadone-intermediate (9254)	II II
Methadone-intermediate (9254) Morphine (9300)	
Methadone-intermediate (9254) Morphine (9300) Thebaine (9333)	II
Methadone-intermediate (9254) Morphine (9300) Thebaine (9333) Levo-alphacetylmethadol (9648)	II II II
Methadone-intermediate (9254) Morphine (9300) Thebaine (9333) Levo-alphacetylmethadol (9648) Oxymorphone (9652)	
Methadone-intermediate (9254) Morphine (9300)	
Methadone-intermediate (9254) Morphine (9300)	
Methadone-intermediate (9254) Morphine (9300) Thebaine (9333) Levo-alphacetylmethadol (9648) Oxymorphone (9652) Noroxymorphone (9668) Alfentanil (9737)	
Methadone-intermediate (9254) Morphine (9300) Thebaine (9333) Levo-alphacetylmethadol (9648) Oxymorphone (9652) Noroxymorphone (9668) Alfentanil (9737)	
Methadone (9250)	

The firm plans to manufacture small quantities of the listed controlled

substances to make deuterated and nondeuterated drug reference standards which will be distributed to analytical and forensic laboratories for drug testing programs.

No comments or objections have been received.

DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Cerilliant Corporation to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Cerilliant Corporation to ensure that the company's registration is consistent with the public interest. This investigation included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. § 823 and 28 CFR §§ 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: June 4, 2001.

Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 01–15835 Filed 6–22–01; 8:45 am]

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Registration

By Notice dated November 8, 2000, and published in the **Federal Register** on November 28, 2000 (65 FR 70936), and by Notice dated December 14, 2000, and published in the **Federal Register** on January 10, 2001 (66 FR 2003), Cerilliant Corporation, 14050 Summit Drive #121, P.O. Box 80189, Austin, TX 78708–0189, made application by renewal to the Drug Enforcement Administration to be registered as an importer of the basic classes of controlled substances listed below:

Drug	Schedule
Cathinone (1235)	 - - -